SAN FRANCISCO -- The increased risk for cardiovascular disease associated with the diagnosis of rheumatoid arthritis was offset by the protective effects of disease-modifying antirheumatic drugs
but heightened by prednisolone therapy in a large community-based study.
It is approved to reduce the signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) in patients four years of age or older who have had an inadequate response to one or more disease-modifying antirheumatic drugs
We need to do more, think differently, think outside the box" of relying primarily on disease-modifying antirheumatic drugs
, especially biological drugs, to resolve symptoms in PsA patients.
The findings are encouraging because patients with rheumatoid arthritis have a higher risk of developing shingles than other adults, and tofacitinib and certain other disease-modifying antirheumatic drugs
are thought to further increase this risk.
Most participants in the study had longstanding RA and were taking disease-modifying antirheumatic drugs
A human monoclonal antibody, Kevzara is indicated for use in patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs
(DMARDs), such as methotrexate (MTX).
The institute is recommending the use of Cosentyx when a patient is suffering from peripheral arthritis with three or more tender joints and three or more swollen joints, and has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs
(DMARDs), administered either as a monotherapy or in combination.
The researchers matched 59,627 patients who received the herpes zoster vaccine with 119,254 unvaccinated patients, based on age, sex, race, calendar year, autoimmune disease type, and use of autoimmune drugs (biologies, disease-modifying antirheumatic drugs
, and glucocorticoids).
Researchers compared the health records of more than 11,000 RA patients taking TNFis with the records of about 3,000 RA patients taking synthetic disease-modifying antirheumatic drugs
(sDMARDs), another common RA treatment.
In this comprehensive review of 3,742 relevant publications, there was general agreement that initial treatment should center on disease-modifying antirheumatic drugs
(DMARDs) plus systemic glucocorticoids.
Kineret is a recombinant protein drug indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs
These patients were compared with 82,258 controls who did not have any of these inflammatory conditions and who were not taking any disease-modifying antirheumatic drugs